Literature DB >> 24597402

Risk-adjusted survival after tissue versus mechanical aortic valve replacement: a 23-year assessment.

Jeffrey G Gaca1, Robert M Clare2, J Scott Rankin3, Mani A Daneshmand2, Carmelo A Milano2, G Chad Hughes2, Walter G Wolfe2, Donald D Glower2, Peter K Smith2.   

Abstract

BACKGROUND AND AIM OF THE STUDY: Detailed analyses of risk-adjusted outcomes after mitral valve surgery have documented significant survival decrements with tissue valves at any age. Several recent studies of prosthetic aortic valve replacement (AVR) also have suggested a poorer performance of tissue valves, although analyses have been limited to small matched series. The study aim was to test the hypothesis that AVR with tissue valves is associated with a lower risk-adjusted survival, as compared to mechanical valves.
METHODS: Between 1986 and 2009, primary isolated AVR, with or without coronary artery bypass grafting (CABG), was performed with currently available valve types in 2148 patients (1108 tissue valves, 1040 mechanical). Patients were selected for tissue valves to be used primarily in the elderly. Baseline and operative characteristics were documented prospectively with a consistent variable set over the entire 23-year period. Follow up was obtained with mailed questionnaires, supplemented by National Death Index searches. The average time to death or follow up was seven years, and follow up for survival was 96.2% complete. Risk-adjusted survival characteristics for the two groups were evaluated using a Cox proportional hazards model with stepwise selection of candidate variables.
RESULTS: Differences in baseline characteristics between groups were (tissue versus mechanical): median age 73 versus 61 years; non-elective surgery 32% versus 28%; CABG 45% versus 35%; median ejection fraction 55% versus 55%; renal failure 6% versus 1%; diabetes 18% versus 7% (p<0.01). Unadjusted Kaplan-Meier survival was significantly lower with tissue than mechanical valves; however, after risk adjustment for the adverse profiles of tissue valve patients, no significant difference was observed in survival after tissue or mechanical AVR. Thus, the hypothesis did not hold, and risk-adjusted survival was equivalent, of course qualified by the fact that selection bias was evident.
CONCLUSION: With selection criteria that employed tissue AVR more frequently in elderly patients, tissue and mechanical valves achieved similar survival characteristics across the spectrum of patient risk. Further studies of the relative outcomes of mechanical versus tissue valves across the spectrum of patient age seem indicated.

Entities:  

Mesh:

Year:  2013        PMID: 24597402      PMCID: PMC4348365     

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  20 in total

1.  Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial.

Authors:  K Hammermeister; G K Sethi; W G Henderson; F L Grover; C Oprian; S H Rahimtoola
Journal:  J Am Coll Cardiol       Date:  2000-10       Impact factor: 24.094

2.  Twenty-five year experience with the St. Jude medical mechanical valve prosthesis.

Authors:  J Matthew Toole; Martha R Stroud; John M Kratz; Arthur J Crumbley; Scott M Bradley; Fred A Crawford; John S Ikonomidis
Journal:  Ann Thorac Surg       Date:  2010-05       Impact factor: 4.330

3.  Performance of bioprostheses and mechanical prostheses in age group 61-70 years.

Authors:  Kriengchai Prasongsukarn; W R Eric Jamieson; Samuel V Lichtenstein
Journal:  J Heart Valve Dis       Date:  2005-07

4.  15-year comparison of supra-annular porcine and PERIMOUNT aortic bioprostheses.

Authors:  W R Eric Jamieson; Eva Germann; Michel R Aupart; Paul H Neville; Michel A Marchand; Guy J Fradet
Journal:  Asian Cardiovasc Thorac Ann       Date:  2006-06

5.  Performance of bioprostheses and mechanical prostheses assessed by composites of valve-related complications to 15 years after aortic valve replacement.

Authors:  V Chan; W R E Jamieson; E Germann; F Chan; R T Miyagishima; L H Burr; M T Janusz; H Ling; G J Fradet
Journal:  J Thorac Cardiovasc Surg       Date:  2006-06       Impact factor: 5.209

6.  Fifteen-year results with the Hancock II valve: a multicenter experience.

Authors:  Giulio Rizzoli; Salvatore Mirone; Paolo Ius; Elvio Polesel; Tomaso Bottio; Loris Salvador; Claudio Zussa; Gino Gerosa; Carlo Valfrè
Journal:  J Thorac Cardiovasc Surg       Date:  2006-09       Impact factor: 5.209

7.  Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database.

Authors:  James S Gammie; Shubin Sheng; Bartley P Griffith; Eric D Peterson; J Scott Rankin; Sean M O'Brien; James M Brown
Journal:  Ann Thorac Surg       Date:  2009-05       Impact factor: 4.330

8.  Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database.

Authors:  James M Brown; Sean M O'Brien; Changfu Wu; Jo Ann H Sikora; Bartley P Griffith; James S Gammie
Journal:  J Thorac Cardiovasc Surg       Date:  2009-01       Impact factor: 5.209

9.  Twenty year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses.

Authors:  H Oxenham; P Bloomfield; D J Wheatley; R J Lee; J Cunningham; R J Prescott; H C Miller
Journal:  Heart       Date:  2003-07       Impact factor: 5.994

10.  Twelve-year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses.

Authors:  P Bloomfield; D J Wheatley; R J Prescott; H C Miller
Journal:  N Engl J Med       Date:  1991-02-28       Impact factor: 91.245

View more
  1 in total

1.  Sparing aortic valve techniques.

Authors:  Rubén Álvarez-Cabo
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.